Omuro et al. reported that administration of nivolumab (an anti-PD-1 antibody) with or without ipilimumab (an anti-CTLA-4 antibody) in patients with recurrent GBM was safe and well-tolerated, but had limited anti-tumor effects on GBM [25]. This evidence concerns the gene CTLA4 and glioblastoma.